Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (symbol: IMNN) is a biopharmaceutical company focused on the research and development of targeted therapies to address unmet medical needs in oncology. With the recent acquisition of EGEN, Inc., Imunon has transformed into a fully integrated company boasting a comprehensive, multi-phase clinical pipeline. The company specializes in nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies. Their platform technologies are designed to leverage the body's natural mechanisms, aiming to generate safe, effective, and durable responses across a wide range of human diseases.
Imunon is committed to innovation and excellence in the field of biotechnology, seamlessly integrating research from the laboratory to clinical applications. By harnessing the building blocks of life, the company strives to work in harmony with the body's immune system to develop groundbreaking treatments.
The company's current projects include a variety of clinical trials that seek to validate the efficacy and safety of their therapies. These efforts are supported by a team of experts with extensive experience in drug development. Imunon's financial health is robust, enabling continuous research and the potential for future growth. Additionally, the company values strategic partnerships that bolster its capabilities and extend its reach in the biotech industry.
For investors and stakeholders, Imunon, Inc. represents a promising opportunity in the field of biopharmaceuticals, with a strong focus on innovative cancer treatments and a commitment to addressing significant healthcare challenges.
IMUNON, a clinical-stage drug-development company, presented findings on its DNA-based immunotherapy, IMNN-001, at the AACR Annual Meeting on April 18, 2023. The study evaluated three dosing regimens for the treatment of advanced ovarian cancer using a mouse model. IMNN-001, in Phase 2 trials, showed that a biweekly dosing regimen was comparable to weekly dosing but more effective than a three-week regimen in reducing tumor burden and mortality. These results support further exploration of biweekly dosing in human studies. Dr. Corinne Le Goff, CEO of IMUNON, expressed excitement over the presentation and highlighted the implications for upcoming clinical studies involving IMNN-001 and bevacizumab.
IMUNON, Inc. (NASDAQ: IMNN) announced its 2022 financial results, reporting a net loss of $35.9 million, or $5.03 per share, an increase from $20.8 million in 2021. Operating expenses rose to $25.4 million, up 18% year-over-year. The company made progress in its clinical programs, including completing enrollment in the Phase 1/2 OVATION 2 Study for IMNN-001 in advanced ovarian cancer. IMUNON reported cash of $38.9 million as of December 31, 2022, expected to fund operations into 2025. The company also highlighted promising preclinical data for its PLACCINE vaccine technology and plans to file an Investigational New Drug (IND) application for a COVID-19 booster vaccine in 2023.
IMUNON (NASDAQ: IMNN), a clinical-stage drug-development company, will host a conference call on March 30, 2023, at 11:00 a.m. ET to discuss its Q4 and full-year financial results for 2022. The company will also update on IMNN-001, its Phase 2 immunotherapy targeting advanced ovarian cancer, and its preclinical studies of PLACCINE, a novel plasmid technology aiming to outperform current mRNA vaccines. Interested parties can join via phone or listen online, with an archived replay available until April 13, 2023. IMUNON focuses on DNA-mediated immunotherapy and next-gen vaccines aimed at various diseases.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
What does Imunon, Inc. specialize in?
What recent acquisition has Imunon, Inc. made?
What is the company's mission?
How does Imunon, Inc. contribute to oncology treatment?
Who are the key players in Imunon, Inc.'s team?
What are the current projects Imunon, Inc. is working on?
How does Imunon, Inc. ensure its financial health?
What makes Imunon, Inc. a good investment opportunity?
How does Imunon, Inc. leverage platform technologies?
What is the significance of Imunon, Inc.'s research and development?
